



IC10 Rec'd PCT/PTO 15 MAR 2002

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <b>10/088564</b>		INTERNATIONAL APPLICATION NO <b>PCT/EP00/08748</b>		ATTORNEY'S DOCKET NUMBER <b>272/068</b>	
---	--	---	--	--	--

<b>21. <input checked="" type="checkbox"/> The following fees are submitted:</b> <b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1) – (5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... <b>\$1040.00</b> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... <b>\$890.00</b> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... <b>\$740.00</b> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... <b>\$710.00</b> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$100.00</b> <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>CALCULATIONS PTO USE ONLY</b>	
				<b>\$890.00</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	6 - 20 =	0	x <b>\$18.00</b>	\$	
Independent claims	1 - 3 =	0	x <b>\$80.00</b>	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ <b>\$270.00</b> \$	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$890.00</b>	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.				\$	
<b>SUBTOTAL =</b>				<b>\$890.00</b>	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
<b>TOTAL NATIONAL FEE =</b>				<b>\$890.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property				\$	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$890.00</b>	
				<b>Amount to be refunded:</b> \$	
				<b>charged:</b> \$	

a. ☐ A check in the amount of \$                      to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 12-2475 in the amount of \$890.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 12-2475. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:  
 KRISTIN H. NEUMAN, ESQ.  
 LYON & LYON, LLP  
 SUITE 4700  
 633 WEST FIFTH STREET  
 LOS ANGELES, CA 90071

SIGNATURE

NAME **CHARLES M. DOYLE**  
 REGISTRATION NUMBER **39,175**  
 DATE **MARCH 15, 2002**

10/088564

JC10 Rec'd PCT/PTO 15 MAR 2002

CERTIFICATE OF MAILING  
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to Box PCT, Commissioner for Patents, Washington, D.C. 20231.

EV 056390695 US  
Express Mail Label No.

March 15, 2002  
Date of Deposit

Russell Morrisette

Name of Person Mailing Paper

*Russell Morrisette*

Signature of Person Mailing Paper

AT/K-22099/M4-2786

11

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number  
WO 01/19895 A1

- (51) International Patent Classification<sup>7</sup>: C08G 65/18, 59/24, 59/62      Brian [GB/GB]; 28 Rushleigh Green, Bishops Stortford, Hertfordshire CM23 4JH (GB).
- (21) International Application Number: PCT/EP00/08748      (74) Common Representative: VANTICO AG; Patents/Scientific Information, Klybeckstrasse 200, CH-4057 Basel (CH).
- (22) International Filing Date: 7 September 2000 (07.09.2000)
- (25) Filing Language: English      (81) Designated States (*national*): AU, CA, JP, KR, US, ZA.
- (26) Publication Language: English      (84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- (30) Priority Data: 9921779.6      16 September 1999 (16.09.1999)      GB      Published:  
— With international search report.
- (71) Applicant (*for all designated States except US*): VANTICO AG [CH/CH]; Klybeckstrasse 200, CH-4057 Basel (CH).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): HATTON, Kevin,

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette*



WO 01/19895 A1

(54) Title: UV-CURABLE COMPOSITIONS

(57) Abstract: The present invention relates to UV-curable compositions, the process for preparing the compositions and to the use of the curable compositions. The compositions contain: a) at least one oxetane compound; b) at least one polyfunctional cycloaliphatic epoxy compound; c) at least one multifunctional hydroxy compound; and d) at least one curing agent.

10/088564

JC10 Rec'd PCT/PTO 15 MAR 2002

UV-Curable Compositions

The present invention relates to UV-curable compositions, the process for preparing the compositions and to the use of the curable compositions.

Sasaki *et al.* *J. Polym. Sci. Part A: Polym. Chem.* **33**, 1807-1816 (1995) report that the UV initiated cationic polymerisation of mixtures of epoxy resins and oxetanes shows faster cure speed than the individual components alone. The U.S. Patent Specifications *US* 5,721,020, 5,882,842 and 5,674,922 describe the use of formulations which contain oxetane compounds to produce UV and electron beam curing systems. It is also known that cycloaliphatic epoxy resins show an increase in cure speeds when formulated with multifunctional hydroxy compounds.

EP-A-0 848 294 describes photocurable resin compositions used for photo-fabrication of three-dimensional objects comprising (A) an oxetane compound, (B) a polymeric epoxy compound having a number average molecular weight of 1000 to 20000, e.g. epoxidated polybutadiene products, and (C) a cationic photo-initiator. Said resin compositions may optionally comprise an epoxy resin different from component (B) including a polyfunctional cycloaliphatic epoxy resin. Furthermore these resin compositions may comprise a polyol for developing the photocurability of the compositions.

It has now surprisingly been found, that certain specific mixtures of cycloaliphatic epoxy resins, oxetanes and multifunctional hydroxy compounds are more reactive and show faster cure speeds even with very low levels of UV cationic photoinitiators. Such compositions when formulated additionally with a cationic photoinitiator show faster cure speed at low levels of photoinitiator when compared with formulations containing no oxetane or oxetane containing formulations which contain cycloaliphatic epoxy compounds or multifunctional hydroxy compounds alone.

The present invention relates to a curable composition comprising


- a) at least one oxetane compound;
- b) at least one polyfunctional cycloaliphatic epoxy compound;
- c) at least one multifunctional hydroxy compound, and
- d) at least one curing agent.

This invention allows for the formulation of UV photoinitiated cationically curable systems with fast cure speeds.

The invention, therefore, allows for the preparation of formulations for UV-photoinitiated cationically curable systems with fast cure speeds.


A preferred embodiment of the invention relates to a curable composition comprising

a) at least one oxetane compound of the formula




wherein R and R' independently of one another represent aliphatic, cycloaliphatic, aromatic or araliphatic groups and n represents an integer from one to four;

b) at least one polyfunctional cycloaliphatic epoxy compound of the formula



wherein R is a straight chain C<sub>2</sub>-C<sub>6</sub> alkylene group; and

c) at least one multifunctional hydroxy compound




in which Q represents an aliphatic, cycloaliphatic or araliphatic group and n an integer from 1 up to 128; and

d) at least one curing agent.

#### Component a)

The oxetane resin is preferably liquid at room temperature and corresponds to compounds of the formula




wherein R and R' independently of one another represent aliphatic, cycloaliphatic, aromatic or araliphatic groups and n represents an integer from one to four. When R and/or R' represent an aliphatic group, it may be straight or branched chain C<sub>1</sub>-C<sub>12</sub>alkylene group.

Cycloaliphatic groups R and/or R' are preferably C<sub>5</sub>-C<sub>8</sub>cycloalkylene groups in which the cycloalkylene ring may be substituted by substituents such as C<sub>1</sub>-C<sub>4</sub> alkyl groups, or several cycloalkylene residues may be bonded together via a bridge member, e.g. a methylene bridge.


Aromatic residues are preferably optionally ring-substituted phenyl residues or naphthyl residues.

Araliphatic residues are preferably optionally ring-substituted benzyl residues or naphthyl methylene residues. The groups R and/or R' may also contain heteroatoms such as oxygen.


Some preferred oxetane resins include but are not limited by the following:




3,3'-[1,4-phenylene-bis(methyleneoxymethylene)]-bis(3-ethyloxetane),




R<sub>1</sub> = Methyl: 3-methyl-3-oxethanemethanol; R<sub>1</sub> = Ethyl: 3-ethyl-3-oxethanemethanol




- 4 -

Component b)


The polyfunctional cycloaliphatic epoxy compound preferably is represented by the formula:




wherein R is a straight chain C<sub>2</sub>-C<sub>6</sub> alkylene group, especially C<sub>4</sub>-alkylene which may be substituted by additional substituents. These epoxy resins may be formed by reaction of peracetic acid with olefinic esters of cycloaliphatic compounds. Some preferred cycloaliphatic epoxy resins are diepoxides and include but are not limited by the following:




7-oxabicyclo[4.1.0]hept-3-ylmethyl ester-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid



2,2'-oxy-bis(6-oxabicyclo[3.1.0]hexane)




bis(7-oxabicyclo[4.1.0]hept-3-yl)-methyl ester hexanedioic acid




2-(3,4-epoxycyclohexyl-5,5-spiro)-(3,4-epoxy)cyclohexane-m-dioxane.



- 5 -




3,3'-(1,3-dioxane-2,5-diyl)-bis(7-oxabicyclo[4.1.0]heptane)

2,2-bis[(7-oxabicyclo[4.1.0]hept-3-ylcarbonyloxy)-methyl]-1,3-propanediol  
ester-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid

Diepoxides containing non-terminal epoxide groups may also be employed such as vinylcyclohexene dioxide, limonene dioxide, dicyclopentadiene oxide, 4-oxatetracyclo[6,2,1,0<sup>2,7</sup>0<sup>3,5</sup>]undec-9-yl glycidyl ether, bis(4-oxatetracyclo[6,2,1,0<sup>2,7</sup>0<sup>3,5</sup>]undec-9-yl)ether of ethylene glycol, 3,4-epoxycyclohexylmethyl-3,4-epoxycyclohexanecarboxylate and its 6,6'-dimethyl derivative, bis(3,4-epoxycyclohexanecarboxylate) of ethylene glycol or 3-(3,4-epoxycyclohexyl)-8,9-epoxy-2,4dioxaspiro[5,5]undecane.

#### Component c)

The multifunctional hydroxyl compounds are those having the formula:



in which Q is an aliphatic, cycloaliphatic or araliphatic residue and n are integers from 1 up to 128. When Q is an aliphatic residue, it may be a straight or branched chain C<sub>2</sub>-C<sub>12</sub>alkylene residue.

Cycloaliphatic residues Q are preferably C<sub>5</sub>-C<sub>8</sub>cycloalkylene residues in which the cycloalkylene group may be substituted by substituents such as C<sub>1</sub>-C<sub>4</sub>alkyl or several cycloalkylene residues may be bonded together via a bridge member, e.g. a methylene bridge.

Araliphatic residues are preferably optionally ring-substituted benzyl residues or naphthyl methylene residues.

Each of the residues Q may be substituted or interrupted provided that the substituent groups or interrupting atoms do not deactivate the heterogeneous catalyst, or undergo competing reactions with the liquid epoxy. Examples of suitable substituent groups are ester

groups as contained in polycaprolactones and unsaturated groups as contained in hydroxy-terminated polybutadienes or polybutadiene polymers.

The alcohols mentioned above may be substituted by alkoxy groups as well as higher polyoxyethylene glycol, polyoxypropylene glycol, polyoxytetramethylene glycol and polycaprolactone groups based on such alcohols.

Specific examples of preferred aliphatic hydroxy compound reactants of formula I (where  $n=1$ ) include methanol, ethanol, propanol, butanol and such straight chain or branched alcohols up to and including  $C_{12}$ alkanols.

Specific examples of cycloaliphatic alcohols include cyclopentanol, cyclohexanol and cycloheptanol as well as such alcohols substituted by  $C_1$ - $C_4$ alkyl and/or alkoxy groups.

Araliphatic alcohols which may be mentioned include benzyl alcohol and phenoxy ethanol both which may have ring substitution such as  $C_1$ - $C_4$ alkyl and/or alkoxy groups, halogens such as F, Cl, Br, I or other groups provided that the substituent groups do not deactivate the heterogeneous catalyst, or undergo competing reactions with the liquid epoxy.

Specific examples of preferred aliphatic dihydroxy compounds reactants of formula I (where  $n=2$ ) include ethylene glycol, diethylene glycol, triethylene glycol and higher polyoxyethylene glycols; propane-1,2-diol; propane-1,3-diol and higher propoxylene glycols; butane-1,4-diol and higher polyoxytetramethylene glycols; polycaprolactone diols; neopentyl glycol; pentane-1,5-diol; hexane-1,6-diol and octane-1,8-diol.

Specific examples of preferred cycloaliphatic diols are e.g. quinitol, resorcitol, bis (4-hydroxycyclohexyl) methane, 2,2-bis(4-hydroxycyclohexyl) propane, cyclohexane dimethanol and 1,1-bis(hydroxymethyl)cyclohex-3-ene and 4,9-bis(hydroxymethyl)tricyclo[5,2,1,0<sup>2,6</sup>]decane.

Araliphatic diol reactants which may be mentioned are 1,4-benzenedimethanol and 4,4'-bis(hydroxymethyl)biphenyl.

Specific examples of preferred aliphatic trihydroxy compounds reactants of formula I (where  $n=3$ ) include glycerol, higher polyethylene glycols based on glycerol, higher polyoxypropylene glycols based on glycerol and polycaprolactone triols also based on glycerol.

Specific examples of preferred aliphatic tetrahydroxy compounds reactants of formula I (where  $n=4$ ) include pentaerythritol, higher polyethylene glycols based on pentaerythritol and higher polyoxypropylene glycols based on pentaerythritol.

Specific examples of preferred aliphatic multihydroxy compounds of formula I (where  $n>4$ ) include a range of dendritic polyols produced by Perstorp Polyols and sold under the Trade

Name BOLTORN (TM) Dendritic Polymers. These include BOLTORN H20, H30, H40 and H50 (OH functionalities = 16, 32, 64 and 128 respectively; and Molecular Weights = 1800, 3600, 7200 and 14400 respectively).

In a preferred embodiment of the process the multifunctional hydroxy compound is selected from the group consisting of pentaerythritol ethoxylate, polyethylene glycol, polytetrahydrofuran, polycaprolactone diol or triol, tripropylene glycol, glycerol propoxylate and dendritic polyols.

The ratio of the oxetane (I) to cycloaliphatic epoxy (II) to multifunctional hydroxy compounds (III) falls within the ranges from 2:1:1 to 300:15:1, more preferably 7.5:1.5:1 to 150:10:1, most preferably 14:2:1 to 91:7:1.

Such compositions which obey the above criteria and when formulated additionally with a cationic photoinitiator show faster cure speed under UV light at lower levels of photoinitiator when compared with formulations containing no oxetane or oxetane containing formulations which contain cycloaliphatic epoxy compounds or multifunctional hydroxy compounds alone. These systems allow for the formulation of fast curing systems with low levels of photoinitiator which gives cured products with low corrosion on sensitive metals such as thin aluminium films, especially after exposing such covered films to high levels of humidity and temperature for extended periods of time. Such systems can alternatively be used to formulate resins which can be used for a stereolithography process where lasers are used to produce 3-dimensional objects for prototyping applications.

A particularly preferred embodiment relates to a curable composition comprising

- a) at least one oxetane compound of the formula I selected from the group consisting of 3,3-[1,4-phenylene-bis(methyleneoxymethylene)]-bis(3-ethyloxetane), 3-methyl-3-oxethanemethanol and 3-ethyl-3-oxethanemethanol;
- b) at least one polyfunctional cycloaliphatic epoxy compound of the formula II selected from the group consisting of 7-oxabicyclo[4.1.0]hept-3-ylmethyl ester-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid, 2,2'-oxy-bis(6-oxabicyclo[3.1.0]hexane), bis(7-oxabicyclo[4.1.0]hept-3-yl)-methyl ester hexanedioic acid, 3,3'-(dioxane-2,5-diyl)-bis(7-oxabicyclo[4.1.0]heptane) and 2,2-bis[(7-oxabicyclo[4.1.0]hept-3-ylcarbonyloxy)-methyl]-1,3-propanediyl ester-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid;
- c) a multifunctional hydroxy compound selected from the group consisting of pentaerythritol ethoxylate, polyethylene glycol, polytetrahydrofuran, polycaprolactone diol or triol, tripropylene glycol, glycerol propoxylate and dendritic polyols; and

d) at least one curing agent.

An especially preferred embodiment of the invention relates to a curable composition comprising

- a) 7-oxabicyclo[4.1.0]hept-3-ylmethyl ester-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid;
- b) at least one polyfunctional cycloaliphatic epoxy compound of the formula II selected from the group consisting of 7-oxabicyclo[4.1.0]hept-3-ylmethyl ester-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid and bis(7-oxabicyclo[4.1.0]hept-3-yl)-methyl ester hexanedioic acid;
- c) a multifunctional hydroxy compound selected from the group consisting of pentaerythritol ethoxylate, polyethylene glycol, polytetrahydrofuran, polycaprolactone diol or triol, tripropylene glycol, glycerol propoxylate and dendritic polyols; and
- d) at least one curing agent.

The curable composition may also contain suitable plasticisers such as dibutyl phthalate and dioctyl phthalate, inert diluents such as tar and bitumen and so-called reactive diluents, especially monoepoxides, such as n-butyl glycidyl ether, iso-octyl glycidyl ether, phenyl glycidyl ether, cresyl glycidyl ethers, glycidyl esters of mixed tertiary, aliphatic, monocarboxylic acids, glycidyl acrylate and glycidyl methacrylate. They may also contain additives such as fillers, reinforcing materials, polymeric toughening agents such as polyether sulphones, phenoxy resins, and butadiene-acrylonitrile rubbers, colouring matter, flow control agents, adhesion promoters, flame inhibitors, and mould lubricants. Suitable extenders, fillers and reinforcing materials are for example, glass fibres, carbon fibres, fibres of aromatic polyamides, ballotini, mica, quartz flour, calcium carbonate, cellulose, kaolin, wollastonite, colloidal silica having a large specific surface area, powdered polyvinyl chloride and powdered polyolefin hydrocarbons such as polyethylene and polypropylene.

The present invention also relates to a process for preparing a curable composition, which comprises

α) treating a composition comprising

- a) at least one oxetane compound;
- b) at least one polyfunctional cycloaliphatic epoxy compound; and
- c) at least one multifunctional hydroxy compound; with

β) an ultraviolet (UV) curable curing agent.

The invention also relates to the use of the curable compositions defined above as adhesives, primers for adhesives, laminating and casting resins, moulding compositions, putties

and sealing compounds, potting and insulation compounds, as coatings or stereolithographic type applications.

The process defined above is performed in a manner known per se. With respect to the cure of the present invention with UV curing agents, any compound that acts as cationic photo-initiator and generates an acid on exposure to actinic irradiation may be used for the preparation of the compositions of the invention. The acid generated may be a so-called Lewis acid or a so-called Broensted acid.

Suitable acid generating compounds include so-called onium salts and iodosyl salts, aromatic diazonium salts, metallocenium salts, o-nitrobenzaldehyde, the polyoxymethylene polymers described in *U.S. Patent Specification No. 3,991, 033*, the o-nitrocarbinol esters described in *U.S. Patent Specification No. 3,849,137*, the o-nitrophenyl acetals, their polyesters, and end-capped derivatives described in *U.S. Patent Specification No. 4,086,210*, sulphonate esters of aromatic alcohols containing a carbonyl group in a position alpha or beta to the sulphonate ester group, N-sulphonyloxy derivatives of an aromatic amide or imide, aromatic oxime sulphonates, quinone diazides, and resins containing benzoin groups in the chain, such as those described in *U.S. Patent Specification No. 4,368,253*.

Suitable aromatic onium salts include those described *U.S. Patent Specification Nos. 4,058,400* and *4,058,401*. Suitable aromatic sulphoxonium salts which can be used include those described in *U.S. Patent Specification Nos. 4,299,938, 4,339,567, 4,383,025* and *4,398,014*. Suitable aliphatic and cycloaliphatic sulphoxonium salts include those described in *European Patent Application Publication No. EP-A-0 164 314*. Aromatic iodonium salts which can be used include those described in *British Patent Specification Nos. 1 516 351* and *1 539 192*. Aromatic iodosyl salts which can be used include those described in *U.S. Patent Specification No. 4,518,676*.

When the acid generating compound is an aromatic diazonium ion, the aromatic group may be unsubstituted or substituted by one or more arylthio, aryloxy, dialkylamino, nitro, alkyl or alkoxy group.

When R is a methallocenium ion, the initiator may have the formula



wherein a is 1 or 2, each of n and q independently of the other is an integer from 1 to 3, M is the cation of a monovalent to trivalent metal from groups IVb to VIIb, VIII or Ib of the Periodic Table, L is a divalent to heptavalent metal or non metal, Q is a halogen atom or one of the groups Q may be a hydroxyl group, m is an integer corresponding to the valency of L + q, R<sup>1</sup> is a  $\pi$ -arene and R<sup>2</sup> is a  $\pi$ -arene or the anion of a  $\pi$ -arene.

Examples of sulphonate esters of aromatic alcohols containing a carbonyl group in a position alpha or beta to the sulphonate ester group and aromatic N-sulphonyloximides are those described in *U.S. Patent Specification No. 4,618,564*, preferably esters of benzoin or alpha-methylolbenzoin, especially benzoin phenyl sulphonate, benzoin-p-toluene sulphonate and 3-(p-toluenesulphonyloxy)-2-hydroxy-2-phenyl-1-phenyl-1-propanone, and N-sulphonyloxy derivatives of 1,8-naphthalimide, particularly N-benzenesulphonyloxy- and N-(p-dodecylbenzenesulphonyloxy)-1,8-naphthalimide.

Examples of aromatic oxime sulphonates are those described in *European Patent Application Publication No. 0 199 672* or non-reactive derivatives of the reactive oxime sulphonates described in the cited publication. Particularly preferred oxime sulphonates are those of formula



wherein one of  $R^3$  and  $R^4$  denotes a monovalent aromatic group, especially phenyl or 4-methoxyphenyl, while the other denotes cyano, or  $R^3$  and  $R^4$ , together with the carbon atom to which they are attached, form a carbocyclic or heterocyclic group, especially a fluorene or anthrone ring system, and  $R^5$  denotes an aliphatic, carbocyclic, heterocyclic or araliphatic group, especially 4-tolyl, 4-chlorophenyl or 4-dodecylphenyl.

The oxime sulphonates can be prepared as described in the above-mentioned *EP-A-0 199 672*. The particularly preferred materials can be prepared by reacting an oxime of formula  $R^3-C(R^4)=NOH$  with a sulphonyl chloride of formula  $R^5SO_2Cl$ , usually in an inert organic solvent in the presence of a tertiary amine.

Examples of quinone diazide compounds include o-benzoquinone diazide sulphonyl or o-naphthoquinone diazide sulphonyl esters or amides of compounds, particularly aromatic compounds, having a hydroxy group or amino group respectively. Preferred are o-quinone diazides such as o-benzoquinone diazide sulphonyl and o-naphthoquinone diazide sulphonyl esters of phenols, including monohydric phenols and, particularly, polyhydric phenols such as 2,2-bis(hydroxyphenyl)propanes, dihydroxydiphenyls, di- and tri-hydroxy-substituted benzophenones, and phenolic resins, including phenol-aldehyde resin and polymers of phenols having polymerisable unsaturated substituents.

Examples of o-nitrophenyl acetals are those prepared from an o-nitrobenzaldehyde and a dihydric alcohol, polyesters of such acetals prepared by reaction of the acetals with a polycarboxylic acid or reactive derivative thereof such as an anhydride, and end-capped derivatives of such acetals prepared by reacting the acetals with a carboxylic acid or reactive derivative thereof. Preferred are acetals derived from o-nitrobenzaldehyde and a linear alkylene

glycol in which the alkylene group has 4 to 15 carbon atoms which may be interrupted by at least one oxygen atom, or a glycol or a cycloalkylenealkylene glycol, and polyester and end-capped derivatives of such acetals.

Preferred linear glycols from which the acetals may be derived are 1,4-butanediol, 1,5-pentanediol, 1,6-hexanediol, 1,7-heptanediol, diethylene and dipropylene glycols and triethylene and tripropylene glycols. Preferred glycols having a cycloaliphatic ring are 2,2,4,4-tetramethyl-1,3-cyclobutanediol, bis(4-hydroxycyclohexyl)methane, 1,4-cyclohexanediol, 1,2-bis(hydroxymethyl)-cyclohexane and, especially, 1,4-bis(hydroxymethyl)cyclohexane.

Examples of polyesteracetals are those prepared by reaction of the preferred acetals described above with an aromatic dicarboxylic or tricarboxylic acid or anhydride thereof, such as phthalic, terephthalic and trimellitic acids and their anhydrides, and mixtures of two or more thereof. An especially preferred polyesteracetal is that prepared by reacting an acetal derived from o-nitrobenzaldehyde and 1,4-bis(hydroxymethyl)cyclohexane with trimellitic anhydride. Preferred end-capped polyacetals are those prepared by reaction of the preferred acetals described above with monobasic carboxylic acid or reactive derivative thereof, such as acetic and benzoic acids and their chlorides.

The amount of the UV curing agent or cationic photoinitiator may be varied over a range depending on the photoinitiator used as is understood by those skilled in the art and varies from 0.01% to 3% or especially 0.1 to 1%. Where such photoinitiators are used, it may be desirable to add a small amount (0.1 to 10 parts by weight, per 100 parts of component 2)) of a sensitiser such as isopropyl-9H-thioxanthen-9-one (ITX) to accelerate the cure.

The curable compositions may contain other curable groups e.g. acrylates and methacrylates which can be cured by UV radical initiators e.g. IRGACURE 184 (TM) as long as the two types of initiator systems do not interfere with each other.

**The following Examples illustrate the invention:**

Studies on the UV cure properties are undertaken using a Differential Photocalorimeter (DPC) attachment on a 2920 Differential Scanning Calorimeter (DSC) supplied by TA Instruments.

An accurately weighed sample of 10(+/-1)mg is placed in aluminium pan, warmed to 30°C and irradiated for 5 minutes with UV light at 60 mW/cm<sup>2</sup>. After irradiation the sample is allowed to stand for 1 minute then warmed to 30°C and then irradiated again to generate the baseline. The baseline is electronically removed from the first run to generate a trace of Heat Flow (W/g) against Time (minutes). The peak exotherm (W/g) so obtained (to the nearest 0.5W/g) is used as a measure of the cure speed for each system under test. Where the higher the value obtained the faster the reaction is proceeding under the action of UV light. The total heat generated (J/g) is a measure of the amount of cure obtained for each system under test.

Where in all cases the ratios are adjusted to show oxetane (OX) : cycloaliphatic epoxy (EP) : alcohol (OH); CYRACURE UVI 6990 (TM) is a mixed triarylsulphonium hexafluorophosphate salt supplied as a 50% solution in propylene carbonate by Union Carbide; CYRACURE UVI 6974 (TM) is a mixed triarylsulphonium hexafluoroantimonate salt supplied as a 50% solution in propylene carbonate by Union Carbide; TPG is tri(propylene glycol); polyTHF (1000) is a polytetrahydrofuran polymer of a molecular weight of 1000; polyTHF (2000) is a polytetrahydrofuran polymer of a molecular weight of 2000; CAPA 200 (TM) is a polycaprolactone diol of molecular weight of 550 supplied by Solvay Interlox; CAPA 305 (TM) is a polycaprolactone triol of a molecular weight 540 supplied by Solvay Interlox; BDMA is butanediol monoacrylate supplied by BASF; IRGACURE 184 (TM) is 1-hydroxycyclohexyl phenyl ketone supplied by Ciba Specialty Chemicals;

Compound F:

3,3'-[1,4-phenylene-bis(methyleneoxymethylene)]-bis(3-ethyloxetane);

Compound G:

3-Methyl-3-oxethanemethanol;

Compound H:

3-Ethyl-3-oxethanemethanol;

Compound A:

7-oxabicyclo[4.1.0]hept-3-ylmethyl ester-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid;

Compound B:

2,2'-oxy-bis(6-oxabicyclo[3.1.0]hexane);

Compound C:



bis(7-oxabicyclo[4.1.0]hept-3-yl)-methyl ester hexanedioic acid;

Compound D:

3,3'-(1,3-dioxane-2,5-diyl)-bis(7-oxabicyclo[4.1.0]heptane)

Compound E:

2,2-bis[(7-oxabicyclo[4.1.0]hept-3-ylcarbonyloxy)-methyl]-1,3-propanediyl  
ester-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid

% means percent by weight if not indicated otherwise.

### Example 1

#### Peak Exotherm Against Oxetane to Cycloaliphatic Epoxy to Alcohol Ratio at 1% CYRACURE UVI 6990 Concentration (50% Propylene Carbonate)

The following formulations were prepared by mixing the ingredients at room temperature to give clear solutions.

Compound F (%)	88	92	89	81	78	72	64
Compound A (%)	7	5	7	13	16	20	26
TPG (%)	4	2	3	5	5	7	9
UVI 6990 (%)	1	1	1	1	1	1	1
Compound F (OX) :	11.8:	25.6:	15.8:	8.8:	8.4:	5.6:	3.8:
Compound A (EP) : TPG (OH)	1.2: 1	1.8: 1	1.6: 1	1.8: 1	2.2:1	2.0 :1	2.0:1
Peak Exotherm (W/g)	16.0	18.5	20.5	20.0	17.5	17.0	18.0

Example 2

Peak Exotherm Against Oxetane to Cycloaliphatic Epoxy to Alcohol Ratio at 1% CYRACURE UVI 6990 Concentration (50% Propylene Carbonate)

Compound F (%)	83	89	88	85
Compound A (%)	13	7	7	7
CAPA (200) (%)	3	3	4	7
UVI 6990 (%)	1	1	1	1
Compound F (OX): Compound A (EP): CAPA(200)(OH)	44.0: 8.8 :1	46.5:4.7:1	35.3:3.6:1	19.0:2.0:1
Peak Exotherm (W/g)	21.0	20.0	22.0	19.0

Example 3

Peak Exotherm Against Oxetane to Cycloaliphatic Epoxy to Alcohol Ratio at 1% CYRACURE UVI 6974 Concentration (50% Propylene Carbonate)

Compound F (%)	81	83	84
Compound A (%)	13	13	13
Benzyl alcohol (%)	5	3	2
UVI 6974 (%)	1	1	1
Compound F (OX): Compound A (EP): Benzyl alcohol (OH)	10.3: 2.1: 1	17.0: 3.4: 1	26.0: 5.2: 1
Peak Exotherm (W/g)	28.0	29.0	27.0

**Example 4**

Peak Exotherm Against Oxetane to Cycloaliphatic Epoxy to Alcohol Ratio at Various CYRACURE UVI 6990 Concentration (50% Propylene Carbonate)

Compound F (%)	70	69.9	69.5	69
Compound C (%)	15	15	15	15
PolyTHF (1000) (%)	15	15	15	15
UVI 6990 (%)	0.0	0.1	0.5	1.0
Compound F (OX) : Compound C (EP) : PolyTHF (1000) (OH)	13.4: 2.8: 1	13.4: 2.8: 1	13.4: 2.8: 1	13.4: 2.8: 1
UVI 6990 (%)	0.0	0.1	0.5	1.0
Peak Exotherm (W/g)	0.0	11.5	15.5	20.0

**Example 5**

Peak Exotherm Against Oxetane to Cycloaliphatic Epoxy to Alcohol Ratio at Either 5% or 0.5% CYRACURE UVI 6990 Concentration (50% Propylene Carbonate).

	Formulation 1	Formulation 2
Compound F (%)	85.5	82
Compound A (%)	9	9
CAPA 305 (%)	4	4
UVI 6990 (%)	0.5	5
Compound F (OX): Compound A (EP) : CAPA 305 (OH)	21.5: 2.9: 1	20.6: 2.9: 1
Peak Exotherm (W/g)	20.0	22.0

Both the above formulations are used to either bond 0.6mm polycarbonate to 0.6mm aluminium (50nm) coated polycarbonate (25 x 25mm overlap) or coat (25mm) 0.6mm aluminium (50nm) coated polycarbonate test pieces (25 x 30mm area). Both samples are cured by passing twice under a Fusion UV lamp (D bulb) at 10m/min.

The test samples are allowed to stand at Room Temperature (RT) for 1 day and are then aged for 4 days in an oven at 80°C and 95% Relative Humidity (RH).

For the bonded samples, Formulation 1 show no signs of either loss or thinning of the aluminium layer, whereas Formulation 2 show both thinning and complete removal of the aluminium at the top and bottom edges of the test sample.

For the coated samples Formulation 1 show no signs of loss or thinning of the aluminium layer, whereas Formulation 2 show significant thinning.

#### Example 6

Peak Exotherm Against Oxetane to Cycloaliphatic Epoxy to Acrylate Containing Alcohol Ratio at Either 6% or 3% CYRACURE UVI 6990 Concentration (50% Propylene Carbonate) and 1% or 3% IRGACURE 184 Concentrations.

	Formulation 3	Formulation 4
Compound F (%)	74	75
Compound A (%)	12	12
BDMA (%)	7	7
CYRACURE UVI 6990 (%)	6	3
IRGACURE 184 (%)	1	3
Compound F (OX): Compound A (EP) : BDMA (OH)	8.6: 1.8: 1	8.8: 1.8: 1
Peak Exotherm (W/g)	25.0	16.0

Formulation 3 and Formulation 4 are further tested as described in Example 5. For the bonded samples Formulation 3 show major thinning and total removal of over half the aluminium layer, whereas Formulation 4 show only thinning of the aluminium. For the coated samples Formulation 3 show both thinning and removal of about 5% of the aluminium, whereas Formulation 4 only show some slight thinning.

## Example 7

Peak Exotherm Against Oxetane to Cycloaliphatic Epoxy to Alcohol Ratio at Either 5% or 1% CYRACURE UVI 6990 Concentration (50% Propylene Carbonate).

	Formulation 5	Formulation 6
Compound F (%)	78	75
Compound C (%)	9	9
PolyTHF (1000) (%)	12	11
CYRACURE UVI 6990 (%)	1.0	5.0
Compound F (OX): Compound C (EP) : PolyTHF (1000) (OH)	17.8: 2.0: 1	17.2: 2.0: 1
Peak Exotherm (W/g)	13	14

Formulations 5 and 6 are used to prepare bonded samples as described for Example 5. Formulation 5 show some slight thinning and removal of the aluminium but only where it had been shaded from the UV light during the cure, whereas Formulation 6 show major thinning and removal of almost half of the aluminium layer.

Example 8

Peak Exotherm Against Oxetane to Cycloaliphatic Epoxy to Alcohol Ratio at 1% CYRACURE UVI 6974 Concentration (50% Propylene Carbonate).

	Formulation 7	Formulation 8	Formulation 9
Compound F (%)	81	77	72
Compound A (%)	8	6	6
PolyTHF (2000) (%)	10	16	21
UVI 6974 (%)	1	1	1
Compound F (OX): Compound A (EP) : PolyTHF (2000) (OH)	45.8: 5.8: 1	27: 2.7: 1	19.7: 2.1: 1
Peak Exotherm (W/g)	30.0	21.5	22.0

The 3-Point Bend test samples are generated on a SLA-250/30 using the HeCad 324 laser. after the parts have been built they are measured for flexural modulus, at 1mm deflection, after standing for the conditions as shown below:

	Formulation 7	Formulation 8	Formulation 9
Flexural Modulus (MPa) after 10 min	1220	620	495
Flexural Modulus (MPa) after 60 min	1370	660	525
After UV Post Cure	1150	690	580
After UV Post Cure + 24 hrs. at RT	1150	710	630

The Dog Bone test pieces are generated on a SLA-250/30 using the HeCad 324 laser. After the parts have been built they are washed in tripropylene glycol monomethyl ether (TPM) for 20 minutes, rinsed with water and dried with compressed air. The samples are placed on a revolving turntable in a UV curing oven for 90 minutes and then allowed to stand, at RT for 24 hours, before being tested.

	Formulation 7	Formulation 8	Formulation 9
Elongation at Break (%)	3.1	6.6	9.8
Break Strength (MPa)	26.8	22.3	16.3
Tensile Modulus (MPa)	1310	966	690
Heat Deflection Temp. (°C)	54	48	42

**Example 9**

Peak Exotherm Against Combinations of Oxetane, Cycloaliphatic Epoxy and Alcohol at 1% Cyracure UVI 6990 Concentration (50% Propylene Carbonate).

	Form. 10	Comp.10a	Comp.10b	Comp.10c	Comp.10d*
Compound F (%)	81	85	93	0	81
Compound A (%)	13	14	0	72	0
Epolead PB3600 (%)	0	0	0	0	13
TPG (%)	5	0	6	27	5
UVI 6990 (%)	1	1	1	1	1
Peak Exotherm (W/g)	20.6	16.9	0.2	15.0	6.9

Epolead PB3600 is an epoxidised Polybutadiene diol supplied by Daicel Chemical Industry Co. Ltd

\*according to prior art reference EP-A-0 848 294

Example 9 shows that the peak exotherm as a measure of the cure speed is greater with the combination of oxetane, cycloaliphatic epoxy and polyol (Form. 10) rather than with a combination of just two of the components alone (Comp. 10a, b, c). This is particularly surprising in the light of the effect that the polyol has on the cure of the oxetane alone where a reaction is almost non-existent (Comp. 10b).


**Claims**

1. A curable composition comprising

- a) at least one oxetane compound;
- b) at least one polyfunctional cycloaliphatic epoxy compound;
- c) at least one multifunctional hydroxy compound, and
- d) at least one curing agent.


2. A curable composition according to claim 1 comprising

- a) at least one oxetane compound of the formula




wherein R and R' independently of one another represent aliphatic, cycloaliphatic or araliphatic groups and n represents an integer from one to four;

- b) at least one polyfunctional cycloaliphatic epoxy compound of the formula



wherein R is a straight chain C<sub>2</sub>-C<sub>6</sub> alkylene group; and

- c) at least one multifunctional hydroxy compound



in which Q represents an aliphatic, cycloaliphatic or araliphatic group and n an integer from 1 up to 128; and

- d) at least one curing agent.



3. A curable composition according to claim 1 comprising

- a) at least one oxetane compound of the formula I selected from the group consisting of 3,3'-[1,4-phenylene-bis(methyleneoxymethylene)]-bis(3-ethyloxetane), 3-methyl-3-oxethanemethanol and 3-ethyl-3-oxethanemethanol;
- b) at least one polyfunctional cycloaliphatic epoxy compound of the formula II selected from the group consisting of 7-oxabicyclo[4.1.0]hept-3-ylmethyl ester-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid, 2,2'-oxy-bis(6-oxabicyclo[3.1.0]hexane), bis(7-oxabicyclo[4.1.0]hept-3-yl)-methyl ester hexanedioic acid, 3,3'-(dioxane-2,5-diyl)-bis(7-oxabicyclo[4.1.0]heptane) and 2,2-bis[(7-oxabicyclo[4.1.0]hept-3-ylcarbonyloxy)-methyl]-1,3-propanediyl ester-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid;
- c) a multifunctional hydroxy compound selected from the group consisting of pentaerythritol ethoxylate, polyethylene glycol, polytetrahydrofuran, polycaprolactone diol or triol, tripropylene glycol, glycerol propoxylate and dendritic polyols; and
- d) at least one curing agent.

4. A curable composition according to claim 1 comprising

- a) 7-oxabicyclo[4.1.0]hept-3-ylmethyl ester-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid;
- b) at least one polyfunctional cycloaliphatic epoxy compound of the formula II selected from the group consisting of 7-oxabicyclo[4.1.0]hept-3-ylmethyl ester-7-oxabicyclo[4.1.0]heptane-3-carboxylic acid and bis(7-oxabicyclo[4.1.0]hept-3-yl)-methyl ester hexanedioic acid;
- c) a multifunctional hydroxy compound selected from the group consisting of pentaerythritol ethoxylate, polyethylene glycol, polytetrahydrofuran, polycaprolactone diol or triol, tripropylene glycol, glycerol propoxylate and dendritic polyols; and
- d) at least one curing agent.

5. A process for preparing a curable composition, which comprises

- α) treating a composition comprising
  - a) at least one oxetane compound;

- 22 -

- b) at least one polyfunctional cycloaliphatic epoxy compound; and
  - c) at least one multifunctional hydroxy compound; with
- β) an ultraviolet (UV) curable curing agent.
6. Use of the curable composition according to claim 1 as adhesives, primers for adhesives, laminating and casting resins, moulding compositions, putties and sealing compounds, potting and insulation compounds, as coatings or stereolithographic type applications.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number  
**WO 01/19895 A1**

(51) International Patent Classification<sup>7</sup>: C08G 65/18,  
59/24, 59/62

Brian [GB/GB]; 28 Rushleigh Green, Bishops Stortford,  
Hertfordshire CM23 4JH (GB).

(21) International Application Number: PCT/EP00/08748

(74) Common Representative: VANTICO AG; Patents/Sci-  
entific Information, Klybeckstrasse 200, CH-4057 Basel  
(CH).

(22) International Filing Date:  
7 September 2000 (07.09.2000)

(25) Filing Language: English

(81) Designated States (*national*): AU, CA, JP, KR, US, ZA.

(26) Publication Language: English

(84) Designated States (*regional*): European patent (AT, BE,  
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE).

(30) Priority Data:  
9921779.6 16 September 1999 (16.09.1999) GB


(71) Applicant (*for all designated States except US*): VAN-  
TICO AG [CH/CH]; Klybeckstrasse 200, CH-4057 Basel  
(CH).

Published:  
— With international search report

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): HATTON, Kevin,

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette*



WO 01/19895 A1

(54) Title: UV-CURABLE COMPOSITIONS

(57) Abstract: The present invention relates to UV-curable compositions, the process for preparing the compositions and to the use of the curable compositions. The compositions contain: a) at least one oxetane compound; b) at least one polyfunctional cycloaliphatic epoxy compound; c) at least one multifunctional hydroxy compound; and d) at least one curing agent.

10/0890 10/0890  
31 JUL 2002

**UTILITY DECLARATION  
AND POWER OF ATTORNEY**  
Utility Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

UV-Curable Compositions

the specification of which

- ☐ is attached hereto OR  
☐ was filed on \_\_\_\_\_ as United States Application Serial No. \_\_\_\_\_ OR  
☒ was filed on 7 September 2000 as PCT International Application No. PCT/EP00/08748  
☐ and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Date of Filing	Priority Claimed	
			Yes	No
9921779.6	Great Britain	16 September 1999	Yes	

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date	Status-Patented, Pending or Abandoned
	PCT/EP00/08748	7 September 2000	Pending

Lyon & Lyon, LLP

POWER OF ATTORNEY: As a named inventor, I hereby appoint as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and transact all business in the United States Patent and Trademark Office, and in countries other than the United States, and to do all things necessary or appropriate therefor before any competent International Authorities in connection with any international patent application(s) corresponding to the above-identified invention application, all of the registered practitioners identified by Customer Number 22249:



**22249**

PATENT TRADEMARK OFFICE

LYON & LYON LLP  
Suite 4700  
633 W. Fifth Street  
Los Angeles, CA 90071  
(213) 489-1600

Please direct all inquiries to Kristin H. Neuman, Esq., at the above Customer Number.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

201	FULL NAME OF INVENTOR	FIRST Name <u>Kevin</u>	MIDDLE Initial <u>B</u>	LAST Name <u>Hatton</u>	
	RESIDENCE & CITIZENSHIP	City <u>Bishops Stortford</u>	State or Foreign Country <u>England</u>	Country of Citizenship <u>Great Britain</u>	
	POST OFFICE ADDRESS	<u>28 Rushleigh Green</u>	City <u>Bishops Stortford</u>	State or Country <u>Hertfordshire</u> <u>England</u>	Zip Code <u>CM23 4JH</u>
INVENTOR'S SIGNATURE		<u>Kevin Brian Hatton</u>			DATE <u>11-3-02</u>

202	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
	RESIDENCE & CITIZENSHIP	City	State or Foreign Country	Country of Citizenship	
	POST OFFICE ADDRESS		City	State or Country	Zip Code
INVENTOR'S SIGNATURE					DATE

203	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
	RESIDENCE & CITIZENSHIP	City	State or Foreign Country	Country of Citizenship	
	POST OFFICE ADDRESS		City	State or Country	Zip Code
INVENTOR'S SIGNATURE					DATE